Skip to main content
. 2022 Dec 2;10(12):e005834. doi: 10.1136/jitc-2022-005834

Figure 3.

Figure 3

Cross presentation by cDC1s is required for CPMV-elicited systemic efficacy (A) Frequencies of DCs, CD11b+DCs, and CD103+DCs among CD45+ cells in B16F10-bearing mice were compared in tumor-draining lymph nodes 48 hours after the second weekly treatment. (B–D). Flank tumor growth curves of CPMV-treated and PBS-treated B16F10 tumors in (B). Batf3−/−, (C). Immune system manipulation using anti-interferon-γ or anti-interleukin-12 depletion antibody correspondingly. Data for bar graphs calculated using unpaired Student’s t-test. Flank tumor growth curves were analyzed using two-way analysis of variance, with p>0.05 as ns, p<0.05 as *, p<0.01 as **, and p<0.001 as ***. All experiments are repeated at least once and each with n≥3 mice/group. aIFNg, anti-interferon gamma; aIL-12, anti-interleukin 12; cDCs, cDCs, conventional dendritic cells; CPMV, cowpea mosaic virus; PBS, phosphate-buffered saline.